AGP Executive Report
Last update: 10 hours agoUS Pharma Tariff Relief: The US Commerce Department has published a Federal Register list granting 0% ad valorem tariffs on select speciality medicines and related ingredients from India and 19 other jurisdictions, even as a broader 100% tariff on certain patented pharma lines is set to start Sept 29. What’s Covered: The zero-duty categories include orphan drugs for rare diseases, fertility treatments, cell and gene therapies, antibody-drug conjugates (ADCs), certain medical countermeasures, and veterinary pharmaceuticals—plus key manufacturing components. Liechtenstein in the Mix: Liechtenstein is named among the eligible jurisdictions, alongside Switzerland and the EU. Healthcare Staffing Pressure: Separately, EU-area worker limits in Ireland’s healthcare sector are being temporarily relaxed to tackle severe staff shortages, with nursing homes and home-care services hit hardest. Rare Disease Treatment Update: The European Commission granted marketing authorization for NEZGLYAL® (leriglitazone) for early male cerebral adrenoleukodystrophy (cALD), with Germany expected to be the first launch market.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
